CN104721428A - Slimming composite granules and preparing method thereof - Google Patents
Slimming composite granules and preparing method thereof Download PDFInfo
- Publication number
- CN104721428A CN104721428A CN201510177447.0A CN201510177447A CN104721428A CN 104721428 A CN104721428 A CN 104721428A CN 201510177447 A CN201510177447 A CN 201510177447A CN 104721428 A CN104721428 A CN 104721428A
- Authority
- CN
- China
- Prior art keywords
- yeast
- slimming
- rhizoma amorphophalli
- granule
- amorphophalli powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000002131 composite material Substances 0.000 title abstract 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 6
- 230000003579 anti-obesity Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 229920002752 Konjac Polymers 0.000 abstract description 4
- 244000247812 Amorphophallus rivieri Species 0.000 abstract description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 abstract description 3
- 239000000252 konjac Substances 0.000 abstract description 3
- 235000010485 konjac Nutrition 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 235000013312 flour Nutrition 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 19
- 235000013339 cereals Nutrition 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 5
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 4
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001264 benfluorex Drugs 0.000 description 1
- CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960001877 fenfluramine hydrochloride Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- -1 yeast cell wall Chemical compound 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to slimming composite granules and a preparing method thereof. The slimming composite granules are made from, by weight, 0.1 to 10 parts of Konjac flour and 1 part of yeast; the two materials are proportionally mixed according to a formula and made into granules. The slimming composite granules have a synergistic effect, help evidently improve the treatment effect, allow slimming to be achieved with low dosage, short treatment course and high effecting speed and have low side effects on the body of a patient.
Description
Technical field
The present invention relates to a kind of composition grain with antiobesity action and preparation method thereof, belong to medicine or food technology field.
Background technology
21 century, obesity has become one of most important public health challenge.Fat closely related with metabolic syndrome (cardiovascular risk factors comprises hypertension, fat metabolic disturbance and insulin resistance), and can the life-span be reduced.According to estimates, have the American of 2/3 overweight or fat, in addition, along with developing country more and more adopts western diet and life style, bariatric patients's quantity will increase further.Estimate according to World Health Organization (WHO), in global range, Overweight and obesity crowd is more than 1,400,000,000.
Current multiple appetrol are quit listing, and doctor's difficulty has more therapeutic choice, and expert claims, the body weight of lasting reduction at least 5%, can reduce obesity and the cardiovascular disease relevant to obesity and diabetes risk.According to the guidance that regulator delivers, reduce 5% minimum standards of just losing weight of body weight, clinician and patient then have higher expectation, and they wish that fat-reducing effect is more obvious, namely at least reduce 10% of body weight.Commercially can the moderate medicine of curative effect in, because its tolerance is poor, safety is low, lack the reasons such as new therapy, inhibit the market development of obesity treatment drugs in itself.And the exploitation of disturbance to this market and new drug of quitting listing one after another of appetrol in recent years makes the matter worse especially.The subject matter of appetrol is its long-term safety.In past 40 years, 5 kinds of appetrol are withdrawn from the market because of potential safety hazard.Wherein, foremost two kinds of medicines are the Pondimin(fenfluramine of Wyeth's (being purchased by Pfizer)) and Redux(dexfenfluramine) withdrew from the market in 1997 years.These two kinds of medicines are found to increase valve disorder risk, and listing is only just withdrawn from the market for 1 year.The appetrol of quitting listing recently have the Meridia/Reductil(sibutramine of Abbott Laboratories), quit listing in 2010 due to cardiovascular disease may be caused; The Mediator(benfluorex of Servier company), owing to quitting listing in 2009 by cardiac trigger valvular heart disease; The Acomplia(Rimonabant of Sai Nuofei), quit listing in 2008 due to depression or suicidal idea may be caused.Most popular phentermine, belongs to the derivant of amphetamines, recent decades because of its cheap but not evident in efficacy or safe and reliable and use.Other conventional fat reduction therapy medicines are lipase inhibitor orlistat (Xenical on market and nonprescription drugs Alli), because orlistat often can cause gastrointestinal upset (as fecal incontinence or oiliness stool), also limit it and use further.But, along with sibutramine quitting listing in Europe, orlistat has become the medicine that this area uniquely may be used for losing weight.
In China market, in January, 2009, due to serious adverse reactions such as meeting cardiac trigger infringements, SFDA requires in China, forbids production and sales and uses fenfluramine hydrochloride tablets and crude drug thereof.On October 30th, 2010, SFDA gives notice, and determine to stop sibutramine preparation and crude drug in the producing and selling of China and use, the medicine of list marketing, is responsible for recalling destruction by manufacturing enterprise.This paper notifies, terminated the sales histories reaching 10 years with " Sibutramine Hydrochloride " the sibutramine series appetrol that are representative in China.
Below be all chemical drugs, life-time service more or less has untoward reaction or toxic and side effects, and some side effect is also very large, although compound Chinese medicinal preparation untoward reaction is less, general validity is poor.So it is few to find untoward reaction, safety, but eutherapeutic natural drug is the problem needing solution badly.
Summary of the invention
The object of the present invention is to provide a kind of composition grain with antiobesity action newly, said composition granule fat-reducing instant effect, good effect and little to person side effect.
Another object of the present invention is to provide a kind of preparation method of combinations thereof composition granule.
In order to realize foregoing invention object, the invention provides following technical scheme:
Have a composition grain for antiobesity action, be made up of the crude drug of following weight: Rhizoma amorphophalli powder 1 ~ 10 part, 1 part, yeast, make granule, particle diameter is no more than 5mm.
Preferably, in above-mentioned raw materials medicine proportioning, Rhizoma amorphophalli powder 2 ~ 8 parts, 1 part, yeast.
Preferred, in above-mentioned raw materials medicine proportioning, Rhizoma amorphophalli powder 3 parts, 1 part, yeast.
Combinations thereof composition granule obtains by following methods preparation:
Get Rhizoma amorphophalli powder and the yeast crude drug of described proportioning, mix homogeneously, makes granule.Pharmaceutically acceptable carrier can be added or/and adjuvant making in granule process, but not add liquid adhesive.
In above-mentioned raw materials medicine: the extraction of substance containing glucomannoglycan (KGM) that Rhizoma amorphophalli powder general reference is extracted from Rhizoma amorphophalli.Have the materials such as Rhizoma amorphophalli powder, konjaku powder, Rhizoma amorphophalli fine powder, Rhizoma amorphophalli fine powder, Rhizoma amorphophalli extract, Konjac glucomannan, glucomannoglycan in the market, these are all included within the Rhizoma amorphophalli powder category of indication of the present invention.Yeast has another name called ferment, for being rich in the mixture of yeast, comprises the similar substances such as yeast dextran, saccharomyces cerevisiae powder, yeast rich in selenium, yeast cell wall, chromium yeast, concentrate microbial ferment, fruit juice enzyme liquid, cereuisiae fermentum rich in selenoaminoacid, yeast beta-dextran.
The instructions of taking of granule of the present invention is directly pour in mouth by dry granule, use mixing in water for oral taking.
compared with prior art, beneficial effect of the present invention: composition grain of the present invention is the granule be made up of Rhizoma amorphophalli powder, yeast 2 kinds of raw materials, there is following distinguishing feature: after (1) this granule enters gastric, after contained Rhizoma amorphophalli powder absorbs moisture content under the environment of water, its volume is inflatable to about self 100 times, occupy gastric volume, thus make eater produce satiety, reduce the absorption of food total amount, reach the effect reducing energy intake; (2) in granule, contained yeast nutrition enriches, be rich in multiple proteins, some is containing various trace elements, compatibility together with Rhizoma amorphophalli powder, meets after water due to Rhizoma amorphophalli powder and forms gelling material, therefore can make yeast Middle nutrition composition slow releasing, slowly absorbs, supplement human body protein, be unlikely to the malnutrition causing food total amount Deficiency of Intake to cause, and yeast strengthening gastrointestinal activity, avoiding part population because taking the issuable constipation of Rhizoma amorphophalli powder; (3) the more important thing is: also just because of the package action of Rhizoma amorphophalli powder to yeast, if both are used in combination simply, will be not easy dispersed in vivo, directly cause having given play to its due effect, be difficult to supplement basic nutrition element while fat-reducing; And make after diameter is no more than the granule of 5mm, directly can be placed in oral cavity, pour in stomach with water, be conducive to Rhizoma amorphophalli powder dispersion, and due to each granule be a little slow release unit, be conducive to again the stripping of yeast Middle nutrition composition.So, Rhizoma amorphophalli powder, yeast compatibility use, it not simple combination, both respective advantage had been taken into full account, improve for weak point again, make curative effect compared with common konjac compositions product, there is apparent synergism, rapid-action, good effect, and without any side effects to patient body.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on content of the present invention all belong to scope of the present invention.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail.
Embodiment 1-5, is grouped into according to one-tenth each in following table 1 and weight proportion makes corresponding composition grain.
Table 1(unit: part)
Each embodiment is all obtained by following preparation method above:
Get the Rhizoma amorphophalli powder of described proportioning, yeast and microcrystalline cellulose (filler), be pressed into press device the granule that diameter is no more than 5mm, obtain final product.
The composition grain that inventor gets above-described embodiment 1-5 gained carries out curative effect on obesity clinical observation.For the ease of comparing the synergistic function between two kinds of crude drug, individually with two kinds of crude drug, make granule according to identical method, its proportioning raw materials is shown in the comparative example 1 and 2 in above-mentioned table 1.
Methods of clinical observation and result as follows:
1, crowd is observed:
Select Body Mass Index BMI(body weight (kilogram)/height (rice
2)) >30(is fat more than 30) and crowd 270 example, be divided into 9 experimental grouies, each experimental group 30 people.
2, instructions of taking:
1st group to the 5th group: the product taken is corresponding embodiment 1 to embodiment 5 respectively, and dose is each 5g, pours granule into oral cavity when taking, and takes after mixing it with water with 500ml warm water, every day Chinese meal and dinner within first 5 minutes, respectively take once, appetite does not control as usual.
Comparative example 1 and comparative example 2: the samely take mode.
7th group: according to the weight proportion identical with embodiment 3, but do not make granule, but make capsule, take 2 every day, each serving being converted into capsule number when taking with 5g(), instructions of taking is: by capsule mixing in water for oral taking, every day Chinese meal and dinner within first 5 minutes, respectively take once, appetite does not control as usual.
6th group: blank group, do not take any product, appetite does not control as usual.
3, efficacy evaluation:
Weigh before taking, weigh after taking 30 days again, the weight that 2 times are reduced using front and back, as evaluation index, calculates the meansigma methods often organizing crowd's loss of weight, and evaluation often organizes performance status.
4, therapeutic effect is shown in following table 2:
Table 2
In table 2, (1) 1-5 group: compare with comparative example 2,
* *p < 0.01; (2) comparative example 1: compare with the 6th group,
※ ※ ※p < 0.01.
Learnt by statistical data in table 2, take the 1-5 group experimenter of present composition granule, take 30 days continuously, fat-reducing effect is best, and p < 0.01, has significant difference compared with comparative example 2, especially better with the 3rd group of effect.Comparative example 1, compared with the 6th group (blank group), p < 0.01, has significant difference, also effective in cure, but muscle power is poor; Illustrate that Rhizoma amorphophalli powder, ferment compatibility result of use are better, not only lose weight, also significantly improve performance status.7th group is Capsules group, a few inefficacy, and fat-reducing effect organizes zero difference with blank, illustrates to take after making granule just can have beyond thought fat-reducing effect.
Claims (5)
1. there is a composition grain for antiobesity action, it is characterized in that: it is made up of the crude drug of following weight: Rhizoma amorphophalli powder 1 ~ 10 part, and 1 part, yeast, make granule, particle diameter is no more than 5mm.
2. composition grain according to claim 1, is characterized in that: Rhizoma amorphophalli powder 2 ~ 8 parts, 1 part, yeast.
3. composition grain according to claim 1, is characterized in that: Rhizoma amorphophalli powder 3 parts, 1 part, yeast.
4. a preparation method for composition grain according to claim 1, is characterized in that: Rhizoma amorphophalli powder and the yeast crude drug of getting described proportioning, mix homogeneously, makes granule.
5. method according to claim 4, is characterized in that: make in the process of granule and do not add liquid adhesive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510177447.0A CN104721428A (en) | 2015-04-15 | 2015-04-15 | Slimming composite granules and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510177447.0A CN104721428A (en) | 2015-04-15 | 2015-04-15 | Slimming composite granules and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104721428A true CN104721428A (en) | 2015-06-24 |
Family
ID=53446224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510177447.0A Pending CN104721428A (en) | 2015-04-15 | 2015-04-15 | Slimming composite granules and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104721428A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820933A (en) * | 2019-02-27 | 2019-05-31 | 北京曲佳科技有限公司 | Weight-reducing tablet and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130134492A (en) * | 2012-05-31 | 2013-12-10 | (주)네오크레마 | Composition for reducing the body fat and strengthening the physical strength |
-
2015
- 2015-04-15 CN CN201510177447.0A patent/CN104721428A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130134492A (en) * | 2012-05-31 | 2013-12-10 | (주)네오크레마 | Composition for reducing the body fat and strengthening the physical strength |
Non-Patent Citations (3)
| Title |
|---|
| ZMS周明水: "魔芋酵母压片糖培训", 《百度文库》 * |
| 中国标准出版社第一编辑室: "《中国农业标准汇编.果蔬卷.下册》", 31 August 2002, 中国标准出版社 * |
| 张炳盛: "《中药药剂学》", 28 February 2013, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820933A (en) * | 2019-02-27 | 2019-05-31 | 北京曲佳科技有限公司 | Weight-reducing tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN102199519B (en) | Medicinal vinegar and method for preparing the same | |
| CN105031042A (en) | Medicinal composition having weight-loss function and application of medicinal composition | |
| CN103155985B (en) | Rhizoma polygonati nutrition powder and preparation method thereof | |
| CN105767999A (en) | Buccal tablet containing wall-broken ganoderma lucidum spore powder, honey and propolis and production method thereof | |
| CN104855734A (en) | Assisted dog food for fat dogs and preparation method of assisted dog food | |
| CN103168994B (en) | A kind of Weight-reducing health composition and method of making the same | |
| CN105725187A (en) | Blood sugar reducing composition and application in preparation of foods and health-care foods | |
| CN104688970A (en) | Drug combination particles having function of losing weight and preparation method thereof | |
| CN103610051A (en) | Food, healthcare food or medicine composition with lipid-lowering effect as well as preparation methods and applications thereof | |
| CN108324874B (en) | Substitute tea for the treatment of gouty arthritis with mixed syndrome of cold and heat | |
| CN104721428A (en) | Slimming composite granules and preparing method thereof | |
| CN114259540B (en) | Traditional Chinese medicine composition for treating diabetes with syndrome of deficiency of both qi and yin and preparation method and application thereof | |
| CN104825702A (en) | Composition capable of reducing fat and supplying nutrients and preparation method thereof | |
| CN106728387B (en) | A kind of compound medicine with promoting immune function and preparation method thereof | |
| CN110025709B (en) | Preparation method and application of exodonthus urinaria and rhizoma dioscoreae powder | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN107412626A (en) | A kind of invigorating the spleen to clear away damp pathogen composition and its processing method and the application in clearing damp anti-trioxypurine product | |
| CN101904500B (en) | Functional food for enhancing immunity and preparation method thereof | |
| CN105733880A (en) | Composite hazelnut wine brewed from hazelnut meal | |
| CN110720527A (en) | Traditional Chinese medicine weight-losing tea | |
| CN107320665A (en) | Treat precocious pharmaceutical composition of child and preparation method thereof | |
| CN107334887A (en) | A kind of konjaku flour particulate composition and preparation method thereof | |
| CN106387363A (en) | Iodine-enriched selenium-enriched chromium-enriched strengthening agent for eggs, as well as preparation method and use method of iodine-enriched selenium-enriched chromium-enriched strengthening agent | |
| CN105077246B (en) | A kind of Moringa abstinence from alcohol composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |